Travoprost and bimatoprost cause dry eye

Article

The use of travoprost 0.004% and bimatoprost 0.03% can have adverse effects on the ocular surface and can result in dry eye symptoms, according to Samet Ermis and co-workers from the Kocatepe University School of Medicine, Turkey.

The use of travoprost 0.004% and bimatoprost 0.03% can have adverse effects on the ocular surface and can result in dry eye symptoms, according to Samet Ermis and co-workers from the Kocatepe University School of Medicine, Turkey.

A total of 78 patients with primary open angle glaucoma (POAG) were enrolled; 44 patients received travoprost and 34 received bimatoprost. Complete ophthalmic examinations were performed before treatment and one week, one, three and six months after treatment. Intraocular pressure (IOP) was measured using Goldmann applanation tonometry and Schirmer and break-up time tests were performed during all examinations. Conjunctival cytology specimens were taken before and six-months after treatment and graded according to Nelson's classification and globlet cell density was evaluated.

In the travoprost group, mean IOP before treatment was 21.4±1.5 mmHg and 15.4±1.6 mmHg six months following treatment (p<0.05). In the bimatoprost group, mean IOP before treatment was 22.0±1.5 mmHg and 15.5 mmHg±1.4 mmHg six months after treatment (p<0.05). The authors found a statistically significant difference, between the two groups, in globlet cell density, Schirmer test and break-up time (p<0.05).

Although the decrease in IOP is statistically significant for both treatment groups, the study did show that travoprost and bimatoprost therapy can give rise to dry eye symptoms.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.